FirstWave Capital Management LLC Sells 16,337 Shares of Astera Labs, Inc. $ALAB

FirstWave Capital Management LLC trimmed its position in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 59.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 10,953 shares of the company’s stock after selling 16,337 shares during the quarter. Astera Labs comprises about 2.3% of FirstWave Capital Management LLC’s holdings, making the stock its 13th biggest holding. FirstWave Capital Management LLC’s holdings in Astera Labs were worth $5,291,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Greenleaf Trust raised its stake in shares of Astera Labs by 1.8% in the second quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock worth $966,000 after purchasing an additional 36 shares during the last quarter. Glenmede Trust Co. NA boosted its position in shares of Astera Labs by 2.7% during the first quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock valued at $209,000 after buying an additional 51 shares during the last quarter. Keating Financial Advisory Services Inc. bought a new stake in Astera Labs in the 2nd quarter worth about $25,000. Lido Advisors LLC raised its position in Astera Labs by 0.5% in the 4th quarter. Lido Advisors LLC now owns 12,297 shares of the company’s stock worth $2,046,000 after buying an additional 57 shares during the last quarter. Finally, Archer Investment Corp purchased a new position in Astera Labs in the 2nd quarter worth about $30,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Demand for Astera Labs’ Scorpio, Aries and Taurus connectivity platforms is supporting expectations for strong third-quarter growth and strengthening the company’s position in AI data-center infrastructure. ALAB Stock Down 24% in a Month: Should Investors Buy the Dip or Wait?
• Positive Sentiment: The company’s latest quarterly results exceeded expectations, with earnings per share of $0.80 versus the $0.69 consensus estimate and revenue of $392.4 million versus $360.85 million. Revenue rose 104.5% year over year, while management issued third-quarter EPS guidance of $1.16 to $1.21.
• Positive Sentiment: Analyst sentiment remains generally constructive: Astera Labs has a “Moderate Buy” consensus rating and an average price target of $348.33, above recent trading levels. Northland upgraded the shares to outperform with a $350 target, while Morgan Stanley maintained an overweight rating with a $335 target.
• Neutral Sentiment: Despite the favorable growth outlook, ALAB has declined 13.9% since its latest earnings report and 24% over the past month, reflecting elevated valuation expectations and uncertainty about the pace of future growth. The stock’s high beta and elevated earnings multiple may contribute to volatility. Why Is Astera Labs Down Since Its Earnings Report?
• Negative Sentiment: Director Manuel Alba sold 183,000 shares for approximately $51.3 million, reducing his holdings by 41.9%. Director Stefan Dyckerhoff separately sold 12,499 shares worth about $3.4 million. The transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their value as a discretionary bearish signal, but the sales may still weigh on investor sentiment and add near-term supply. SEC Insider Trading Filing

Astera Labs Stock Performance

NASDAQ ALAB opened at $310.40 on Friday. The business’s fifty day moving average is $330.74 and its 200 day moving average is $254.36. Astera Labs, Inc. has a fifty-two week low of $97.89 and a fifty-two week high of $499.48. The company has a market capitalization of $53.85 billion, a PE ratio of 153.66 and a beta of 3.77.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%.The business had revenue of $392.40 million during the quarter, compared to analysts’ expectations of $360.85 million. During the same quarter in the prior year, the business posted $0.44 earnings per share. The business’s quarterly revenue was up 104.5% on a year-over-year basis. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. On average, sell-side analysts forecast that Astera Labs, Inc. will post 2.7 EPS for the current year.

Insiders Place Their Bets

In related news, Director Manuel Alba sold 183,000 shares of Astera Labs stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the transaction, the director owned 253,863 shares in the company, valued at approximately $71,114,642.19. The trade was a 41.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Philip Mazzara sold 6,801 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $340.50, for a total transaction of $2,315,740.50. Following the completion of the transaction, the general counsel directly owned 96,542 shares of the company’s stock, valued at $32,872,551. This represents a 6.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 592,244 shares of company stock valued at $209,729,973. Insiders own 10.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALAB. TD Cowen dropped their price target on shares of Astera Labs from $425.00 to $375.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. Barclays increased their target price on Astera Labs from $200.00 to $325.00 and gave the company an “equal weight” rating in a report on Monday, July 20th. Stifel Nicolaus raised their target price on Astera Labs from $260.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Bank of America upped their price target on shares of Astera Labs from $240.00 to $450.00 and gave the company a “neutral” rating in a research report on Tuesday, June 23rd. Finally, Jefferies Financial Group increased their price objective on shares of Astera Labs from $270.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $348.33.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.